'Clinical development' presentation slideshows

CHEST Guidelines 2012 Update

CHEST Guidelines 2012 Update. Betsy Bryant Shilliday, Pharm.D ., CDE, CPP Bart Scott, MPAS, PA-C Brittain Fish Erickson, MHS, PA-C Carrie Palmer, MSN, RN, ANP-BC, CDE April 4, 2012. http://chestjournal.chestpubs.org/content/141/2_suppl. Objectives.

788 views • 64 slides

Agenda

533 views • 43 slides

604 views • 42 slides

Current and Future Treatment of Chronic Hepatitis C

Current and Future Treatment of Chronic Hepatitis C . John Scott, MD, MSc University of Washington. Case. 43 yo Asian woman w/ chronic Hep C, GT 1, HCV RNA level of 2 million IU/ml ALT 53, INR 1.0, Albumin 4.1 Liver biopsy: grade 2 inflammation, stage 2 fibrosis HTN What to do next?

915 views • 39 slides

One focused pipeline March 2010

Carnegie Nordic Healthcare Seminar Stockholm Wednesday 24 March 2010 Presented by Bertil Samuelsson, VP Discovery & Research Rein Piir, CFO / IR. One focused pipeline March 2010. Our first product have seen the light of the market - launched as Rx in Sweden and Finland.

471 views • 39 slides

Pathology and Imaging In Biomarker Development

Pathology and Imaging In Biomarker Development. C. Carl Jaffe, MD, FACC Cancer Imaging Program National Cancer Institute. Biomarker NIH Workshop definition (2001): .

405 views • 38 slides

Draft Guidance for Industry: CGMPs for Phase 1 INDs

Draft Guidance for Industry: CGMPs for Phase 1 INDs. Joseph C. Famulare, Director Division of Manufacturing & Product Quality Office of Compliance, CDER, FDA Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee 20-21 July 2004. Background.

503 views • 26 slides

BOVIE = ELECTROSURGERY

956 views • 23 slides

Do you have the critical talent you need to:

Do you have the critical talent you need to:. Energize Your Organization Impact Your Bottom Line Lead You Into 2013 and Beyond. It's All About Investing In the Right People.

378 views • 23 slides

60 people Geneva-based

OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable anti-malaria medicines. ?. 300 partners Africa 67 Americas 89 Asia -Oceania 70 Europe 79. 37 projects In pipeline

352 views • 22 slides

Safety Assessment UK Alderley Park Cheshire United Kingdom

Safety Pharmacology Society Webinar Series: Safety Pharmacology Endpoints: Integration into Toxicology Studies Integrating functional CNS observations into toxicology studies: the CONS! Will Redfern, PhD . Safety Assessment UK Alderley Park Cheshire United Kingdom. September 20, 2012.

500 views • 21 slides

Nasdaq: IDRA

368 views • 21 slides

Covidien: Corporate Overview

571 views • 20 slides

Knowledge Update Clinical documentation: from preclinical studies to drug registration

Knowledge Update Clinical documentation: from preclinical studies to drug registration. Split, 12 September 2008. Clinical programme. Registration. Drug discovery. Preclinical development. Company. Regulatory Agency FDA (US) EMEA (EU). Overview of drug development.

405 views • 17 slides

Overview

251 views • 11 slides

Quality by Design Workshop

325 views • 7 slides

Diabetic Retinopathy Therapeutics - Pipeline Assessment and

DR Therapeutics Market is Forecast to Show Significant Growth from 2010 to 2017

530 views • 6 slides

Peripheral Ulcerative Keratitis Therapeutics Market is forecast to Show Slow Growth to 2017, The report identifies the key trends shaping and driving the global PUK market.

524 views • 4 slides

Spinal Muscular Atrophy Drug Pipeline - 2012

Clinical Development. Preclinical: Discovery. Spinal Muscular Atrophy Drug Pipeline - 2012. FDA Approval. Basic Research Seed Ideas. Identification Optimization Safety & Manufacturing. Phase I Phase II Phase III. IND. Trophos/Olesxime. Repligen/Quinazoline*.

202 views • 1 slides

COST Action BM1207

Networking towards clinical application of antisense-mediated exon skipping Involving all key stakeholders (clinicians, scientists, industry, patients & regulators) Facilitate the clinical development of antisense-mediated exon skipping for rare diseases

159 views • 1 slides